Is MRD Ready for Prime Time? Evaluating the Clinical Utility of Ultrasensitive MRD Testing in Breast Cancer Treatment
ASBRS 2026 ANNUAL MEETING
FRIDAY EVENING SYMPOSIUM*
Join Myriad Oncology™ in examining the evolving role of tumor informed molecular residual disease (MRD) testing in the treatment of breast cancer. A multidisciplinary panel discussion will address current evidence, technical and practical considerations, and future directions for the incorporation of MRD testing into surgical and postoperative care pathways.
*This symposium is supported by Myriad Oncology™ through a marketing grant. It is not part of the official ASBrS Annual Meeting program, and no AMA PRA Category 1 Credits™ are assigned to it by the ASBrS.
Dinner and beverages will be provided. This symposium is exclusively for registered ASBrS 2026 attendees.
Seats are limited. RSVP now.
About Myriad Oncology™
Myriad Oncology, a business unit of genetic testing and precision medicine leader Myriad Genetics, provides an expanding portfolio of advanced genetic and tumor genomic testing solutions, meeting the specific needs of clinicians and their oncology patients. Myriad Oncology products support each step in the cancer care continuum, empowering clinicians and their patients with confidence and clarity to navigate the unique challenges of each cancer journey. For more information, visit https://myriad.com/oncology/.
We Are Live In
Myriad Genetics, Inc. / 322 North 2200 West, Salt Lake City, UT 84116 ©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.